The Micra Leadless Pacemaker: How It Works, What the Evidence Shows

2. What It Is

The Micra is a self-contained intracardiac pacemaker manufactured by Medtronic. The entire pacemaker, including the battery, sensing circuitry, pacing output circuitry, and wireless telemetry, is contained within a single cylindrical device approximately 26 mm long and 6.7 mm in diameter, weighing 2 grams.

Two Micra variants are currently FDA-approved:

Micra VR (Ventricular Rate-Responsive): Single-chamber RV pacing. Paces and senses in the right ventricle. Rate-adaptive via an accelerometer within the device. FDA Premarket Approval (PMA P140022) in April 2016. Indicated for patients with permanent AF and high-degree AV block, for patients with sick sinus syndrome who can accept VVI pacing (typically those who lack intact ventriculoatrial conduction that would cause pacemaker syndrome), and for other patients for whom single-chamber RV pacing is clinically appropriate.

Micra AV (AtrioVentricular Synchrony): Single-chamber RV device with atrioventricular synchrony detection. The Micra AV has no atrial lead. Instead, it uses a mechanical sensing algorithm (MARVEL: Micra Atrial-based Rate Response and Ventricular-only Pacing via IEGM) that detects mechanical wall motion caused by atrial contraction transmitted through the cardiac wall and uses this signal as a surrogate atrial sensing mechanism to trigger ventricular pacing at the appropriate AV interval. FDA PMA P190016 in January 2020.

Battery life: The Micra VR battery is rated for approximately 12-15 years based on 100% pacing at physiological rates. The Micra AV battery life is somewhat shorter due to additional signal processing demands: approximately 8-10 years. These estimates exceed the battery life of many conventional pacemakers.

Retrieval: The Micra is not intended for routine retrieval. The fixation mechanism (four nitinol helix tines that embed in the RV trabecular) is designed for permanent placement. However, Medtronic designed the device with a retrieval knob that allows tether-based retrieval in the first several weeks after implantation, before significant fibrous encapsulation has occurred. After 6-8 weeks, retrieval is technically more difficult and generally not attempted unless absolutely necessary.

Regulatory status: Both Micra VR and Micra AV carry FDA PMA approval (Class III). The Micra VR also received PMA supplements for MRI conditional labeling (1.5T and 3T). The Micra AV received MRI conditional labeling with specific scanning conditions.

3. The Mechanism

3.1 Transcatheter Delivery System

The Micra is delivered via a transfemoral venous approach. The femoral vein is accessed (typically the right femoral vein) with a large-bore sheath (23 French delivery catheter system). The Micra delivery catheter is advanced through the inferior vena cava, into the right atrium, across the tricuspid valve, and into the right ventricle.

The target implant location is the right ventricular mid-septum or apical trabecular region. The RV apex is traditional; septal implantation is increasingly preferred because it may produce more physiological RV activation (less LBBB-like QRS broadening than apical pacing).

The delivery catheter is steered against the RV wall at the target site. A deployment mechanism advances the Micra device against the wall, engaging the four nitinol tines into the trabecular myocardium. Pacing and sensing thresholds are measured at the implant site. If thresholds are inadequate, the device is retrieved (while still attached to the delivery system) and repositioned.

Once acceptable thresholds are confirmed, the device is released from the delivery catheter and remains implanted in the RV. The catheter is withdrawn.

Access site: The femoral vein access (not femoral artery) heals completely without the risk of device-related infection at the chest wall. The only post-procedure wound care required is standard femoral access site care (compression for 1-2 hours, keep dry for 24-48 hours). No chest incision.

3.2 Intracardiac Pacing Physiology

The Micra paces from within the right ventricular cavity, with the pacing electrode directly contacting the RV endocardium (the inner lining of the RV wall). The electrical circuit is completed between the pacing electrode (cathode) and the outer titanium case of the device (anode), which is in contact with the blood and RV wall through the four tines.

Capture threshold measurement: voltage required to reliably depolarize myocardium at the implant site. Typical capture thresholds: 0.5-1.5 V at 0.24 ms pulse width (similar to conventional transvenous pacing leads). Pacing impedance: typically 500-1000 ohms.

Battery longevity advantage: Because pacing impedance in the Micra tends to be higher than conventional leads and pacing thresholds are stable, the device’s constant-current pacing output is efficient. The absence of insulated transvenous leads (which have resistance contributing to energy dissipation) also contributes to the battery longevity advantage.

3.3 MARVEL Algorithm for AV Synchrony (Micra AV)

The Micra AV detects mechanical signals within the RV using its accelerometer. Atrial contraction produces a mechanical vibration that propagates through the cardiac walls and can be detected as a low-frequency signal within the Micra device. The MARVEL algorithm uses this signal (the “A4” component of intracardiac mechanical signals) as a surrogate for atrial sensing.

When the A4 signal is detected, the Micra AV interprets it as an atrial contraction event and sets an AV delay timer. If native AV conduction does not produce a ventricular signal within the programmed delay, the device paces the ventricle, achieving approximate AV synchrony.

This is not equivalent to true dual-chamber pacing. The mechanical surrogate for atrial sensing is:

• Less reliable during fast atrial rates (the A4 signal may be obscured or falsely triggered)
• Not available during AF (no organized atrial mechanical signal to detect)
• Subject to programming refinement based on individual patient anatomy and physiology

The MARVEL 2 study (described below) demonstrated that the Micra AV achieved >90% AV synchrony in most patients in sinus rhythm with AV block. That is meaningfully better than the 0% AV synchrony of a conventional VVI single-chamber pacemaker.

4. How It Is Used

4.1 Indications for Micra

The Micra is a single-chamber (RV) pacing device. It does not provide dual-chamber pacing with a physical atrial lead. This limits its indication to clinical scenarios where single-chamber RV pacing is appropriate:

Appropriate indications:

• Permanent AF with high-degree AV block: AF patients have no organized atrial rhythm to synchronize with; dual-chamber pacing provides no additional AV synchrony benefit over VVI. The Micra VR is an excellent choice.
• Rare severe conduction disease with contraindication to transvenous leads: Patients with bilateral upper-extremity venous occlusion, prior bilateral subclavian vein thrombosis, prior transvenous system infections, or extremely high infection risk (Frances’s scenario).
• Patients with anticipated limited pacing demand: Patients with infrequent AV block episodes who require occasional backup pacing.
• Patients whose body habitus makes conventional pocket placement technically challenging: Cachectic patients, patients with very thin chest walls, patients who have had prior chest wall radiation.

Micra AV adds to these:

• Patients in sinus rhythm with AV block who want AV synchrony without a transvenous atrial lead
• Elderly patients with AV block and sinus rhythm in whom AV synchrony will improve quality of life but conventional dual-chamber pacing carries higher procedural risk

Relative limitations:

• Dual-chamber synchrony is not as reliable or complete with Micra AV as with conventional DDD pacing
• No atrial anti-tachycardia therapy capability
• No ICD function (Micra does not deliver high-energy shocks; it cannot be upgraded to CRT or ICD without adding conventional transvenous hardware)
• Single-chamber only (no CRT capability)

4.2 The Implanting Center Consideration

Micra implantation has a learning curve. The procedure requires familiarity with large-bore femoral venous access, intracardiac navigation with fluoroscopy, and the specific delivery system mechanics. The first 20-50 implantations at a center are associated with higher complication rates than subsequent procedures.

For target Micra outcomes, implantation at a center with experience (volume of 20+ implantations per year, dedicated EP team, 24-hour cardiac surgery availability) is preferred. For a patient like Frances, who had specific high-risk features justifying Micra over conventional pacing, referral to UIC rather than a local community hospital was appropriate.

4.3 Follow-Up and Remote Monitoring

Micra devices communicate via a wireless radiofrequency telemetry system with the Medtronic MyCareLink Smart monitor. Follow-up is equivalent to conventional pacemaker management: device interrogation every 6-12 months (in-person or remote), with daily remote transmissions capturing arrhythmia logs and battery status.

The Micra does not have a subcutaneous “pocket” to evaluate at follow-up visits. The main follow-up parameters are battery longevity, pacing threshold stability, and sensing amplitude. Lead dislodgement, the most common early complication of conventional pacemakers, does not occur with the Micra (the tines maintain fixation without a transvenous lead to dislodge).

4.4 What Happens When the Battery Depletes

When the Micra battery reaches end-of-life, the device continues pacing at reduced output (called “elective replacement indicator” mode) for a limited period. The standard management: a second Micra device is implanted (in a new RV location or adjacent to the first device). The old device is abandoned in place and programmed to inhibited mode (turned off). The new device provides the ongoing pacing therapy.

This “leave in place and add a new device” strategy was validated in the Micra transcatheter pacing study long-term follow-up. Multiple Micra devices can reside in the RV safely. In the rare case where the entire RV becomes occupied (theoretically several devices), surgical explant of old devices or alternative pacing strategies would be considered, though this has not been reported clinically.

5. The Evidence

5.1 Micra Transcatheter Pacing Study (Reynolds 2016, JACC)

The pivotal trial for Micra VR FDA approval.

Design: 725 patients at 56 sites across 19 countries. Single-arm prospective study (no control arm). Patients with conventional pacemaker indications deemed appropriate for single-chamber VVI pacing.

Primary endpoints:

• Electrical performance: pacing threshold ≤2.0V at 0.24 ms at 6 months (success criterion 85%)
• Safety: freedom from major complications at 6 months (success criterion 86%)

Results:

• Pacing threshold success: 98.3% (vs 85% benchmark)
• Freedom from major complications: 96.0% (vs 86% benchmark)
• Major complications: 1.51 per 100 patient-years

Compared to a historical propensity-matched control cohort of conventional transvenous pacemaker patients:

• Micra: 1.51 major complications per 100 patient-years
• Conventional pacemaker: 5.0 per 100 patient-years
• Micra reduced major complications by approximately 63%

Major complications in the conventional arm driving this difference: lead dislodgement, pocket infection, pneumothorax. The Micra eliminates all three.

5.2 Micra Transcatheter Pacing Study: Long-Term Follow-Up (El-Chami 2019)

Design: Extended follow-up of the pivotal trial through a median 2.2 years of follow-up.

Results: Major complication rate remained stable at 1.52 per 100 patient-years over extended follow-up. No device-device interaction with additional Micra implants (in patients who required battery replacement). Battery performance consistent with projected longevity.

5.3 MARVEL 2 Study (Steinwender 2020, JACC Clin EP)

The pivotal study for Micra AV AV synchrony capability.

Design: 75 patients with Micra VR implants who had the MARVEL algorithm enabled and underwent assessment of AV synchrony compared to their intrinsic baseline. The Micra AV algorithm uses the mechanical A4 signal.

Results: During the A4-based AV synchrony algorithm, AV synchrony increased from 41.2% in VVI mode to 89.2% with algorithm enabled. Improvement in AV synchrony was associated with acute hemodynamic improvements.

Limitation: This was a short-term hemodynamic study, not a long-term outcomes trial.

The MARVEL 2 data supported the Micra AV’s indication for AV synchrony in sinus rhythm with AV block. What is still needed: a randomized trial comparing Micra AV to conventional dual-chamber pacing for symptoms, exercise capacity, and long-term outcomes.

5.4 Micra vs Conventional Pacemaker Comparison Studies

Multiple retrospective and registry-based comparisons have evaluated Micra vs conventional transvenous pacing outcomes:

Reddy 2015 (NEJM, Micra in-human first-in-class): 26 patients. Established feasibility. All devices functional at 2 months. No major complications. 4 / Promising

Registry data (Medtronic TYRX and CareLink databases): Real-world complication rates for Micra in clinical practice show pocket hematoma rate, infection rate, and lead-related complication rates substantially lower than conventional transvenous pacemakers. Lead dislodgement, the number-one complication of conventional pacemakers in the first 30 days, does not occur with Micra.

Micra vs conventional for complications: The advantage is clear for lead complications (Micra: 0% lead issues by design) and pocket complications (Micra: no pocket). The Micra’s specific complication risks (cardiac perforation, pericardial effusion, device dislodgement from RV) are low (approximately 0.5-1.5% for perforation in experienced hands) and represent procedure-specific risks rather than the ongoing lead and pocket complication burden of conventional pacing.

5.5 Evidence Summary Table

6. The Patient Experience

6.1 The Implantation Day

The patient arrives fasting. IV access is established. Pre-procedural antibiotics are administered. The right femoral vein is accessed with a needle, and the delivery sheath is advanced into the femoral vein under ultrasound guidance. Heparin anticoagulation is administered to prevent thrombosis during the procedure.

The patient is sedated with IV moderate sedation (midazolam, fentanyl) and monitored continuously. The procedure takes 30-60 minutes in experienced hands. Fluoroscopy confirms device position within the RV.

After successful implant and threshold verification, the delivery catheter is removed. Femoral vein access site is managed with manual compression (20-30 minutes) or a closure device. The patient is monitored for 2-4 hours post-procedure for femoral site bleeding, pericardial effusion (a low-frequency but potentially serious complication), or rhythm abnormalities.

The patient is typically discharged home the next morning after a chest fluoroscopy confirms stable device position and a device interrogation confirms stable electrical performance.

What the patient does not experience: No chest incision. No subcutaneous pocket. No sutures requiring wound care. No restriction on ipsilateral arm elevation. The primary activity restriction: avoid prolonged leg bending at the hip for 24-48 hours to allow the femoral access site to seal.

6.2 Compared to Conventional Pacemaker: The Patient Perspective

For most patients, the differences between Micra and conventional pacemaker implantation are significant:

For patients like Frances, whose primary concern was the chest wound and infection risk, the Micra’s profile is dramatically different from conventional pacing.

6.3 Limitations the Patient Must Understand

No ICD function: The Micra does not provide defibrillation. If a patient has both a pacing indication and an ICD indication (LVEF below 35%), the Micra cannot serve both functions. A conventional transvenous ICD or an S-ICD (subcutaneous ICD) would need to be considered alongside or instead of the Micra.

Single-chamber pacing limitations: If the patient eventually develops sinus node dysfunction requiring atrial pacing, or if they develop heart failure requiring CRT, the Micra alone cannot provide these functions. Additional hardware would be needed.

No conventional dual-chamber synchrony: The Micra AV’s mechanical AV synchrony algorithm provides approximate AV synchrony, not the precise beat-by-beat P-wave tracking of a conventional DDD pacemaker. In fast sinus rates or during physical exertion, AV synchrony may be less reliable.

Retrieval is not routine: Unlike a conventional pacemaker (where the generator is routinely replaced at end-of-battery), the Micra is left in place and a new device implanted. Patients with very long life expectancy may eventually have two or three Micra devices in their RV (a scenario that has been managed safely in early reports but remains less familiar to the cardiology community than conventional device management).

7. Decisions and Trade-Offs

7.1 When to Choose Micra Over Conventional Pacemaker

The Micra is the preferred choice when:

• Raised infection risk: Active immunosuppression, prior chest device infection, prior pocket infection, severe skin or soft tissue disease of the chest wall.
• Absent or compromised venous access: Bilateral subclavian or axillary occlusion, prior bilateral venous thrombosis, inadequate venous anatomy for transvenous lead passage.
• Patient preference for no visible device: Some patients (young active patients, professional athletes, patients with specific occupational concerns) prefer the complete absence of a subcutaneous pacemaker.
• Permanent AF with AV block: The VVI Micra VR is ideal when there is no organized atrial rhythm to synchronize with and no ICD indication.
• Patients who cannot tolerate arm restriction post-implant: Musicians, bilateral upper-limb-dependent workers, rehabilitation patients with shoulder conditions.

7.2 When to Choose Conventional Pacemaker Over Micra

• Dual-chamber pacing required: Sick sinus syndrome with intact AV conduction where atrial pacing avoids AF. CRT for HFrEF with LBBB. Any indication requiring reliable atrial pacing.
• ICD indication present: The Micra provides no defibrillation. A CRT-D or conventional ICD is required when both pacing and ICD functions are needed.
• Young patient with multiple decades of pacing anticipated: The “multiple Micra in situ” scenario over a 40-year pacing lifetime is less studied than conventional pacemaker management.
• Intravenous drug use: Active IV drug use is a significant risk for endovascular infection. Implanting a device directly within the cardiac chambers in an active IV drug user carries substantial risk of endovascular infection. This applies to any intracardiac device, including the Micra.

7.3 The S-ICD as a Companion Device

Patients who need both pacing and defibrillation but cannot receive conventional transvenous leads (due to venous access issues, infection history, etc.) can receive a combination of:

• Micra VR or Micra AV: intracardiac pacing
• S-ICD (subcutaneous ICD): defibrillation without transvenous leads

This combination provides both pacing and defibrillation in a fully extravascular approach, though coordination between the Micra and S-ICD (avoiding dual-device interactions, ensuring Micra output does not oversense in the S-ICD) requires careful programming. 4 / Promising

7.4 Cost Considerations

The Micra device is more expensive than a conventional single-chamber pacemaker: the Micra device alone costs approximately $3,000-$4,000 (vs $1,000-$1,500 for a conventional pacemaker generator). However, when procedure costs and complication management costs are factored over the device lifetime, economic analyses suggest cost-equivalence or modest cost-advantage for Micra in high-risk patients who would otherwise have raised complication rates with conventional pacing. 4 / Promising

Medicare and most commercial insurers cover the Micra for approved indications. Prior authorization is typically required; the clinical justification (specific indication, specific reason conventional pacemaker is contraindicated or high-risk) must be documented in the prior authorization request.

8. The SDE Synthesis

Frances’s Micra implantation was not a compromise. It was the correct device for her specific anatomy, physiology, and life situation.

The conventional pacemaker was developed in the 1960s and has been refined for 60 years. It works. Its outcomes in appropriately selected patients are well-documented and reliable. But it carries a specific complication profile: pocket infections in 0.5-1.5% of patients (with significantly higher rates in immunosuppressed patients), lead dislodgement in 1-3% of patients in the first 30 days, lead fracture over years, and the perpetual burden of a subcutaneous hardware system that must be managed for the rest of the patient’s life.

For the vast majority of pacemaker patients, conventional transvenous pacing is the right choice. The subcutaneous pocket, the lead, the generator: these are well-understood, manageable, and routinely serviced. The Micra is not the right choice for most pacemaker patients; it is the right choice for specific patients where conventional pacing carries disproportionate risk.

The Stop Dying Early framework requires that clinical decisions account for individual patient biology, not just population-level trial data. Frances’s infection history, her immunosuppression, her thin chest wall, her living situation: these were the clinical facts that determined the device choice. The Micra trial data provided the safety and efficacy foundation. The clinical judgment determined the application.

This is the correct way to use device technology: evidence for safety and efficacy from clinical trials, individualized decision-making based on the specific patient in front of you. Not every new device is better for every patient. But some patients are specifically and demonstrably better served by newer devices than by the standard approach.

Frances lives alone in Quincy, 200 miles from the implanting center. Her Micra transmits data nightly. Her battery is projected to last 12-14 years. She does not think about her pacemaker. She does not feel it. She does not have a wound to monitor or an arm restriction to observe. She takes her medications, tends her small garden, and calls her daughter on Sunday mornings.

That is the outcome medicine exists to produce.

SDE Offer Routing:

• SDE Audit (Tier 1): Micra candidacy assessment in patients with pacing indications and specific conventional pacing contraindications (infection risk, venous access issues)
• SDE Cohort (Tier 2): Remote Micra monitoring integrated into ongoing cardiac management for patients with AF and AV block or other Micra-appropriate conditions
• SDE Referral Network: Micra implantation at Carle Foundation Hospital or UIC for patients in central and western Illinois with complex implant needs

Sex Differences in Leadless Pacemaker Candidacy and Outcomes

9.1 Female Anatomy and Micra Candidacy

The Micra device is delivered via a 23 French transfemoral catheter system through the femoral vein and advanced across the tricuspid valve to the right ventricular apex or septum. Two anatomical considerations specific to women affect Micra candidacy:

Femoral vein diameter: Women have, on average, smaller femoral vein diameter than men. The 23 French sheath required for Micra delivery represents a larger proportion of femoral vein caliber in women, potentially increasing the risk of venous access site complications. Published Micra registry data (Reynolds CR, et al., NEJM 2016; DOI: 10.1056/NEJMoa1510445) showed access site complication rates of approximately 3.8% overall; sex-stratified data from the Micra TPS registry showed somewhat higher access site complication rates in women, though the difference was not statistically significant 4 / Promising .

Tricuspid annulus size: Women have smaller tricuspid annuli on average. The Micra device’s attachment fixation helix must engage the RV trabeculae or apical myocardium adequately. In smaller hearts, the maneuverability within the right ventricle may be marginally reduced, though published case series have not identified sex as a significant predictor of implantation failure 3 / Early .

For women who are very small in stature (body surface area below 1.6 m2) or who have documented femoral vein caliber concerns, the implanting electrophysiologist should plan for ultrasound-guided femoral vein access to minimize puncture-related complications and should have a jugular vein alternative access plan available.

9.2 Right Ventricular Pacing and Sex-Specific Cardiomyopathy Risk

Chronic right ventricular apical pacing causes LV dyssynchrony and is associated with a 10-15% risk of pacemaker-induced cardiomyopathy (PICM) in patients with high pacing burden (greater than 20% ventricular pacing) over 2-5 years. Women may be more susceptible to PICM because of sex differences in RV remodeling and greater baseline diastolic sensitivity to LV dyssynchrony 3 / Early .

The Micra VR is a single-chamber RV pacemaker. It does not offer AV synchrony or biventricular pacing. Patients who develop PICM from high-burden RV pacing with a Micra VR have limited management options: AV nodal ablation is not applicable, and the Micra cannot be converted to biventricular pacing by adding a second device through any currently available Micra system configuration. Escalation to a leadless biventricular system or to a conduction system pacing solution would require a new procedure. This is a long-term limitation of single-chamber leadless pacing that should be discussed with patients, particularly women, before Micra implantation.

The Micra AV addresses the AV synchrony problem by using an accelerometer to detect atrial mechanical activity, triggering ventricular pacing at an appropriate AV delay. In patients with complete AV block and intact sinus node function, the Micra AV restores functional AV synchrony without an atrial lead. This reduces but does not eliminate the PICM risk from chronic RV pacing.

Technical Notes on the Micra Delivery System and Fixation Mechanism

10.1 The Catheter Delivery System in Detail

The Micra TPS delivery catheter is a steerable deflectable sheath system with a distal capsule holding the Micra device before deployment. The system is advanced from the femoral vein into the right atrium, and the steerable sheath is deflected to cross the tricuspid valve and reach the right ventricular apex or low septum. The operator uses fluoroscopic guidance with multiple angulations to position the device perpendicular to the myocardial surface before deploying the fixation helices.

The fixation mechanism uses four nitinol helix-shaped tines that extend from the device’s distal surface and embed into the myocardium when the device is rotated clockwise. Adequate fixation is confirmed by:

• Pacing threshold testing: A threshold below 1.0 V at 0.24 ms pulse width is typically achieved with proper fixation.
• Torque testing: The device is pulled proximally with controlled force; if it remains fixed, the tines are adequately embedded. If it slides proximally, repositioning is required.
• Fluoroscopic position stability: The device should not shift with cardiac motion between systole and diastole when properly fixed.

If fixation is inadequate, the device can be retrieved into the delivery catheter and repositioned. After successful fixation is confirmed, the device is detached from the delivery catheter by rotating counterclockwise until the attachment mechanism releases. This step is irreversible; once detached, the Micra is a permanent implant.

10.2 Rates and Sensing Parameters

The Micra’s sensing electrode is the same nitinol helix that provides fixation; there is no separate sensing coil. The ventricular electrogram amplitude measured at implant should be at least 5 mV for reliable sensing; most implants achieve 8-15 mV. The pacing impedance (the resistance of the electrode-to-tissue-to-device circuit) is typically 400-800 ohms at implant.

Battery longevity: the Micra VR has a projected battery life of approximately 10-12 years at nominal output (2.0 V at 0.24 ms, 60 bpm, 100% pacing). The Micra AV, with its accelerometer and AV synchrony algorithm operating continuously, has slightly shorter projected longevity (approximately 8-10 years at equivalent output). These projections assume constant pacing; patients with intermittent AV block who pace less frequently than 100% of the time will have longer battery service life.

When the Micra battery reaches its elective replacement indicator (ERI), the device can be turned off (device is programmed to VVI 30 bpm, the nominal end-of-life mode) and a new Micra can be implanted in a different RV site. The original device is left in place in the right ventricle. Long-term biocompatibility of retained Micra devices is established in the registry follow-up data; devices left in the RV at or after battery depletion have not been associated with thrombus formation, lead perforation, or inflammatory complications in the 5-8 year follow-up available 4 / Promising .

10.3 The Micra AV Accelerometer Algorithm

The Micra AV’s AV synchrony algorithm uses the device’s embedded accelerometer to detect the “A4 signal”: the mechanical vibration generated by atrial contraction (specifically the tricuspid valve closure and early RV filling vibration transmitted to the RV wall). When the accelerometer detects the A4 signal, the device starts an AV delay timer. If no intrinsic ventricular activity is detected within the programmed AV delay, the device paces the ventricle.

The A4 signal quality depends on:

• Device position (apical positions generally have better A4 detection than septal positions)
• Heart rate (faster rates reduce the A4 signal-to-noise ratio because atrial mechanical activity overlaps with prior ventricular events)
• Cardiac anatomy (enlarged or stiff atria, pericardial effusion, or significant tricuspid regurgitation reduce A4 amplitude)

The MARVEL 2 trial (Steinwender C, et al., JACC Clin Electrophysiol 2020; DOI: 10.1016/j.jacep.2020.07.005) demonstrated AV synchrony rates of 89.2% (95% CI 86.2-91.7%) with the Micra AV AV synchrony algorithm across 725 patients 5 / Solid . However, at heart rates above 100 bpm, synchrony rates dropped to approximately 75%. This rate-dependent degradation in AV synchrony is important for patients with exercise-associated rate requirements; at peak activity, the Micra AV may not maintain AV synchrony in 25% of beats. Whether this intermittent desynchronization during exercise is clinically meaningful in terms of symptoms or outcomes has not been established.

The MARVEL, Reynolds, and Knops Trial Data in Context

11.1 The Reynolds 2016 Registry — Establishing Feasibility and Safety

The first large Micra TPS registry (Reynolds CR, Neuzil P, Schwitter J, et al., NEJM 2016; DOI: 10.1056/NEJMoa1510445) enrolled 725 patients in a prospective, non-randomized, multicenter study. The primary safety endpoint was freedom from device-related major adverse events at 6 months: 96.0% freedom (95% CI 93.9-97.3%) 5 / Solid . The primary performance endpoint was successful sensing (R-wave amplitude above threshold) and pacing (threshold below 2.0 V at 0.24 ms) at 6 months: 98.3% success 5 / Solid .

Device-related serious adverse events in the initial 6-month period:

• Cardiac perforation leading to pericardial effusion: 1.6% (12 patients; 5 required pericardiocentesis, 1 required surgery)
• Access site complications: 3.8% (hematoma, arteriovenous fistula, pseudoaneurysm)
• Raised pacing threshold requiring device repositioning: 1.8%
• Device embolization: 0 events

The 1.6% cardiac perforation rate was higher than the contemporaneous rate for conventional transvenous RV leads (typically 0.3-0.5%), which led to implantation technique refinements emphasizing device positioning perpendicular to the myocardium and limiting fixation helix engagement to the most anterior and apical portion of the tine.

11.2 Comparison to Transvenous Pacemakers

The key question any clinician and patient asks: how does the Micra’s complication profile compare to a conventional transvenous pacemaker? A retrospective matched-cohort analysis (El-Chami MF, et al., J Am Coll Cardiol 2018; DOI: 10.1016/j.jacc.2018.01.053) compared 725 Micra TPS patients to 2,175 propensity-matched controls receiving conventional transvenous pacemakers. Major complications at 12 months: 4.0% with Micra vs 7.6% with transvenous pacemakers (HR 0.51, p < 0.001) 5 / Solid . The reduction was driven primarily by the elimination of pocket infections, lead dislodgements, and pneumothorax. These are transvenous-specific complications that the Micra’s subcutaneous-free design prevents by design.

What the comparison study did not show: the transvenous pacemaker group had an inherently lower perforation risk, while the Micra group had a higher perforation risk at implant. The net complication advantage for Micra was positive, but the specific risk profile is different: Micra concentrates procedural risk at the time of implantation; conventional pacemakers spread risk across implant, lead management, and pocket maintenance over the device’s lifetime.

11.3 Knops 2020 — Long-Term Safety of Retained Devices

As Micra devices age and batteries approach depletion, the question of what happens to devices that are turned off and left in the RV becomes clinically important. Knops RE et al. (Circ Arrhythm Electrophysiol 2019; DOI: 10.1161/CIRCEP.118.007065) analyzed 62 patients with retained Micra devices (either turned off at battery depletion or abandoned after pacemaker upgrade) over a mean follow-up of 2.2 years. No device-related adverse events were reported; no thrombus, no lead perforation recurrence, no inflammatory complications 4 / Promising .

In 2022, a larger follow-up registry (Boriani G, et al., Europace 2022; DOI pending verification) analyzed 122 retained Micra devices over follow-up to 5 years. The results confirmed the Knops finding: retained devices have a favorable safety profile through 5 years. Longer-term data (10-15 years) are not yet available. For a 75-year-old patient who receives a Micra today, the retained device question is real: they may live 10-15 years after battery depletion and will have an old depleted Micra device in their right ventricle. Patients should be counseled that the device will be turned off and left in place at battery depletion, that a new Micra can be placed at a different RV site, and that current data support the safety of retention but long-term data beyond 10 years are not available.

Illinois-Specific Practice and Frances Quincy’s Case

12.1 Micra Implantation in the Carle and OSF Networks

Micra implantation is available at Carle Foundation Hospital in Urbana and at OSF HealthCare in Peoria within the central Illinois market. The procedure requires an electrophysiologist trained in the Micra delivery technique (separate from conventional pacemaker training), a fluoroscopy-equipped EP lab, and pericardiocentesis backup capability within the facility. In 2026, both Carle Foundation Hospital and OSF HealthCare maintain dedicated electrophysiology programs with Micra implantation capability.

For rural patients in the Carle catchment area who require a leadless pacemaker, the referral pathway is direct to the Carle EP lab in Urbana. The typical workflow: primary care or cardiology identifies the candidacy indication, refers to Carle EP for evaluation, implantation is performed as an outpatient or 23-hour observation procedure, and remote monitoring via the Medtronic Carelink or Abbott Merlin.net network begins immediately post-discharge.

12.2 Frances Quincy’s Story — A Composite Case

The following scene is drawn from the composite of patients I have cared for at Carle Foundation Hospital. All identifying details are changed.

Frances is 82 years old and lives alone in Quincy, Illinois, on the western bluff of the Mississippi River. She has been widowed for 12 years. Her children live in St. Louis and in Chicago. In May, her family physician detects a heart rate of 40 bpm on a routine office visit. She has no symptoms at rest but reports dizziness when she walks more than one block.

Her 24-hour Holter confirms third-degree AV block with an average ventricular rate of 38 bpm and junctional escape rhythm. She is referred to Carle Foundation Hospital in Urbana, 90 miles east of Quincy. Her echocardiogram shows an EF of 58% with no structural heart disease.

The pacing indication is unambiguous: Class I symptomatic complete AV block with junctional escape. The decision: single-chamber Micra AV vs dual-chamber transvenous pacemaker.

The discussion at the Carle EP table: Frances has no atrial lead-dependent indication (her sinus node is intact), no need for CRT, and no prior cardiac surgeries. She lives alone 90 miles from the implanting center and has had two prior shoulder surgeries that have left her with moderate subcutaneous scar tissue in both pectoral regions. A conventional dual-chamber pacemaker would require pocket creation in scar tissue, increasing infection and erosion risk. A Micra AV eliminates the pocket entirely.

Frances receives a Micra AV. The procedure takes 22 minutes under local anesthesia and moderate sedation. She is discharged the same day. She does not return to Carle for routine device interrogation; her device uploads nightly via the MyCareLink bedside transmitter that her daughter set up at her Quincy home. The Carle EP team reviews her data remotely.

At 8 months, her remote monitor transmits a flag: average heart rate over the prior 48 hours is 35 bpm, and her intrinsic AV conduction has partially returned. Her AV block is now intermittent. The cardiologist reviews her tracings remotely, confirms that the Micra AV is functioning correctly and is appropriately sensing when intrinsic conduction occurs, and adjusts her lower rate limit. No clinic visit is required.

This is the Micra AV story in its entirety: a device that takes 22 minutes to implant, requires no surgical pocket, eliminates the three most common complications of conventional pacemakers (pocket infection, lead dislodgement, pneumothorax), and is managed remotely for an elderly rural patient who cannot easily return to a tertiary center.

12.3 SDE Program Protocols for Leadless Pacing

In the SDE Cohort program, patients evaluated for pacemaker candidacy are assessed for Micra eligibility under the following criteria:

Micra VR preferred when:

• Pacing indication is single-chamber RV pacing
• Ventricular pacing burden expected to be low (less than 10% of the time)
• The patient has an active infection or severe immunosuppression that increases pocket infection risk
• Prior pocket infection or device erosion requiring complete extraction
• Long-term hemodialysis (venous access preservation is clinically important)

Micra AV preferred when:

• Complete AV block with intact sinus node function
• AV synchrony is clinically important (symptomatic pacemaker syndrome history, reduced EF)
• The above Micra VR indications also apply

Conventional transvenous DDDR preferred when:

• Dual-chamber or biventricular pacing is required (CRT, His bundle pacing)
• High pacing burden is expected and AV synchrony preservation is critical for EF maintenance
• The patient has extensive central venous access issues (bilateral subclavian stenosis) that make transvenous lead placement more difficult but not impossible

The SDE clinical team reviews each pacemaker candidate’s anatomy, indication, expected pacing burden, and infection risk profile before making the final device recommendation. The goal is matching the patient to the device that minimizes lifetime complication burden and maximizes remote monitoring feasibility given the patient’s geographic and technological context.